ホームページ Biosimilar抗体 Angiogenesis VEGFR Ramucirumab (anti-VEGFR2) For research use only.
Not for use in humans.

Ramucirumab (anti-VEGFR2)

製品コードA2003 別名: IMC-1121B, LY3009806, IMC-1121

Ramucirumab is a monoclonal antibody of the IgG1 class that binds to VEGF-R2 and prevents its activation. The IC50 value for blocking KDR binding to VEGF is 0.8 nM for ramucirumab, MW : 143.6 KD.

Ramucirumab (anti-VEGFR2)

当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

文献中Selleckの製品使用例（4）

質量管理及び製品安全説明書

現在のバッチを見る： 純度： 99.4% タンパク質濃度： 5mg/ml 内毒素： ≤1 EU/mg
99.4

VEGFR阻害剤の選択性比較

生物活性

製品説明 Ramucirumab is a monoclonal antibody of the IgG1 class that binds to VEGF-R2 and prevents its activation. The IC50 value for blocking KDR binding to VEGF is 0.8 nM for ramucirumab, MW : 143.6 KD.
Targets
KDR/VEGF interaction
0.8 nM
In Vitro
In Vitro Ramucirumab is direct inhibitor of VEGF-R2, where it binds to the extracellular VEGF-binding domain with high degree of specificity and affinity, at picomolar dose range. It thus prevents the binding of the VEGF ligand to the VEGF-R2 receptor. Ramucirumab has potential advantages over bevacizumab as it is selective for VEGF-R2, whereas bevacizumab by targeting VEGF-A affects VEGF-R1, -R2, and the noncatalytic coreceptors neuropilin-1and -2. Ramucirumab prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D to its receptors. Thus, ramucirumab inhibits the angiogenesis pathways involved in the development and progression of gastric cancer. ramucirumab demonstrates inhibition of VEGF-stimulated VEGFR-2 activation, proliferation of human endothelial cells, VEGF migration of human leukemia cells, and VEGF induced phosphorylation of VEGFR-2 in human umbilical vein and porcine aortic endothelial cells overexpressing VEGFR-2. Preclinical in vitro data revealed that ramucirumab has a high affinity for VEGFR-2, showing a half-maximal effective concentration (EC50) of 0.15 nM, 8- to 9-fold higher than its natural ligand VEGFA. Ramucirumab binds VEGFR-2 in domain 3 near the N-terminus, both as a soluble protein and as a cell-surface receptor, with a IC50 of 1-2 nM.
細胞実験

The anti-KDR antibodies were added to the microwells of a 96-well plate coated with KDR(Ig1-7) (full-length KDR ECD), KDR(Ig1-3) (variant that contains only the first three N-terminal Ig domains of KDR ECD), or KDR(Ig1) (variant that contains only the first N-terminal Ig domain of KDR ECD) and incubated at room temperature for 1 h. The plate was washed and then incubated with a mouse anti-human Fc antibody-HRP conjugate for additional 1 h, after which the plate was developed as described above. Antibody binding to the two Ig deletion variants are shown as relative (as percentages) to their binding to the full-length KDR ECD.
In Vivo
In Vivo In preclinical studies, ramucirumab concentrations of >20 μg/mL were associated with anticancer activity. And ramucirumab potently inhibited VEGF binding to VEGFR-2 with a binding affinity constant of ramucirumab to VEGFR-2 of 5 × 10-11 M. Pharmacokinetic evaluation has demonstrated a nonlinear pharmacokinetic, with incremental doses of this agent being associated with a decrease in clearance. Ramucirumab has a half-life of 200-300 h. Preclinical studies were also to be conducted in mice, but interspecies receptor differences made ramucirumab inactive in preclinical mouse models.
  • https://pubmed.ncbi.nlm.nih.gov/25281695/
  • https://pubmed.ncbi.nlm.nih.gov/26413377/
  • https://pubmed.ncbi.nlm.nih.gov/20624120/
  • https://pubmed.ncbi.nlm.nih.gov/27144874/
  • https://pubmed.ncbi.nlm.nih.gov/12917408/

製品説明

CAS No. 947687-13-0
Formulation PBS buffer, pH 7.2
Isotype human IgG1
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Sterility 0.2 μM filtered

各種クローンの論文数比較

*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07594548 NOT_YET_RECRUITING Drug: Futibatinib|Drug: Paclitaxel Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Esophageal Adenocarcinoma; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Carcinoma Northwestern University 2027-09-09 PHASE1
NCT07603856 RECRUITING Drug: Investigator Choice Immunotherapy (for example: pembro Non-Small Cell Lung Cancer; Metastatic Lung Cancer University of Chicago 2026-12-12 PHASE2
NCT05719558 RECRUITING Drug: ASP1002|Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Leuc Advanced Solid Tumors Astellas Pharma Global Development, Inc. 2023-03-13 PHASE1
NCT07546812 RECRUITING Drug: Denikitug|Drug: Nivolumab|Drug: Ramucirumab|Drug: Pacl HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma; Gastric Adenocarcinoma Gilead Sciences 2026-08-07 PHASE2
NCT06962137 RECRUITING Drug: zolbetuximab Gastric Cancer Adenocarcinoma Metastatic; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma Universitaire Ziekenhuizen KU Leuven 2025-12-11 PHASE2
NCT07763171 NOT_YET_RECRUITING Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|Drug: Gastroesophageal Adenocarcinoma Gruppo Oncologico del Nord-Ovest 2026-09-01 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-05-18)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください